et al., medRxiv, doi:10.1101/2020.11.29.20235218 (Preprint) (meta analysis - not included in study count)
6th independent analysis showing efficacy from the Boulware PEP trial.
This prospective analysis corrects an error in the NEJM paper where shipping delays are omitted (still not corrected).
42% reduction in COVID-19 (9.6% vs. 16.5%), RR 0.58 [0.35 - 0.97], p
=0.044, for the original trial 3 day specification.
Wiseman et al., 12/2/2020, preprint, 4 authors.
risk of COVID-19 case, 42.0% lower, RR 0.58, p = 0.04, <= 3 days after exposure.